NCT00632892

Brief Summary

Clinically, iodinated contrast-medium (CM) is widely used in angiography and computerized tomography. CM-induced nephropathy (CMIN) is one major complication after application of CM. Therefore, how to prevent CMIN is always one of the hot topics concerned by nephrologists, cardiologists, and radiologists. The present study is aimed to determine the norepinephrine concentration, oxidative markers, and tubular damage markers in the urine samples of patients undergoing intravenous pyelography (IVP). The working hypothesis is high-osmolarity contrast media (HOCM) causes more oxidative stress and greater tubular damage than iso-osmolarity contrast media (IOCM).

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2007

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2008

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

March 3, 2008

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 11, 2008

Completed
Last Updated

March 11, 2008

Status Verified

February 1, 2008

Enrollment Period

1 month

First QC Date

March 3, 2008

Last Update Submit

March 10, 2008

Conditions

Kidney Diseases

Keywords

oxidative stress markers in urineurine norepinephrinerenal tubular enzyme markers

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

1. Adult patients (\> 18 years old) 2. Undergoing IVP with an appropriate medical indication 3. Signing informed consent

You may qualify if:

  • Adult patients (\> 18 years old)
  • Undergoing IVP with an appropriate medical indication
  • Signing informed consent

You may not qualify if:

  • \. Without signing informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Far Eastern Memorial Hospital

Pan Chiao, Taipei, 220, Taiwan

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

The urine samples are collected just before and 30 minutes after IVP.The samples are immediately frozen at -80'C until analyzed.

MeSH Terms

Conditions

Kidney Diseases

Condition Hierarchy (Ancestors)

Urologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

March 3, 2008

First Posted

March 11, 2008

Study Start

December 1, 2007

Primary Completion

January 1, 2008

Last Updated

March 11, 2008

Record last verified: 2008-02

Locations

TW(1)